IL12RB2 and cancer: Also, in the context of cancer, IL-12 has antiangiogenic properties that are being harnessed for experimental therapeutic purposes (33–35), which must overcome proangiogenic properties of IL-35 (23, 36) and cannot occur in the absence of IL-12Rβ2 binding (37).